Immunitas Therapeutics procures $58m Series B

Immunitas Therapeutics, a single cell genomics-based therapeutics company, has secured $58 million in Series B financing.

Immunitas Therapeutics, a single cell genomics-based therapeutics company, has secured $58 million in Series B financing. Agent Capital led the round with participation from other investors that include Medical Excellence Capital, 120 Capital, Solasta Ventures, Mirae Asset and Ono Venture Investment.

Source: Press Release